Pasar al contenido principal

MODULACION DE LOS RECEPTORES ACOPLADOS A PROTEINAS G POR LIGANDOS Y PROTEINAS ASOCIADAS

BES-2017-081872

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Allosterism in the adenosine A2A and cannabinoid CB2 heteromer

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Lillo Jové, Jaume|||0000-0001-7712-0850
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
Background and Purpose: Allosterism is a regulatory mechanism for GPCRs that can be attained by ligand-binding or protein-protein interactions with another GPCR. We have studied the influence of the dimer interface on the allosteric properties of the A2A receptor and CB2 receptor heteromer. Experimental Approach: We have evaluated cAMP production, phosphorylation of signal-regulated kinases (pERK1/2), label-free dynamic mass redistribution, β-arrestin 2 recruitment and bimolecular fluorescence complementation assays in the absence and presence of synthetic peptides that disrupt the formation of the heteromer. Molecular dynamic simulations provided converging evidence that the heteromeric interface influences the allosteric properties of the A2AR-CB2R heteromer. Key Results: Apo A2AR blocks agonist-induced signalling of CB2R. The disruptive peptides, with the amino acid sequence of transmembrane (TM) 6 of A2AR or CB2R, facilitate CB2R activation, suggesting that A2AR allosterically prevents the outward movement of TM 6 of CB2R for G protein binding. Significantly, binding of the selective antagonist SCH 58261 to A2AR also facilitated agonist-induced activation of CB2R. Conclusions and Implications: It is proposed that the A2AR-CB2R heteromer contains distinct dimerization interfaces that govern its functional properties. The molecular interface between protomers of the A2AR-CB2R heteromer interconverted from TM 6 for apo or agonist-bound A2AR, blocking CB2R activation, to mainly the TM 1/7 interface for antagonist-bound A2AR, facilitating the independent opening of intracellular cavities for G protein binding. These novel results shed light on a different type of allosteric mechanism and extend the repertoire of GPCR heteromer signalling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Leu/Val6.51 Side Chain of Cannabinoid Receptors Regulates the Binding Mode of the Alkyl Chain of Δ9-Tetrahydrocannabinol

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Lillo, Jaume
  • Rebassa, Joan Biel
  • Ferreiro-Vera, Carlos
  • Sánchez de Medina, Verónica
  • Franco, Rafael|||0000-0003-2549-4919
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
(-)-Δ-trans-tetrahydrocannabinol (THC), which is the principal psychoactive constituent of Cannabis, mediates its action by binding to two members of the G-protein-coupled receptor (GPCR) family: the cannabinoid CB (CBR) and CB (CBR) receptors. Molecular dynamics simulations showed that the pentyl chain of THC could adopts an I-shape conformation, filling an intracellular cavity between Phe and Trp for initial agonist-induced receptor activation, in CBR but not in CBR. This cavity opens to the five-carbon chain of THC by the conformational change of the γ-branched, flexible, Leu side chain of CBR, which is not feasible by the β-branched, mode rigid, Val side chain of CBR. In agreement with our computational results, THC could not decrease the forskolin-induced cAMP levels in cells expressing mutant CBR receptor but could activate the mutant CBR receptor as efficiently as wild-type CBR. Additionally, JWH-133, a full CBR agonist, contains a branched dimethyl moiety in the ligand chain that bridges Phe and Val for receptor activation. In this case, the substitution of Val to Leu in CBR makes JWH-133 unable to activate CBR. In conclusion, our combined computational and experimental results have shown that the amino acid at position 6.51 is a key additional player in the initial mechanism of activation of GPCRs that recognize signaling molecules derived from lipid species.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB Receptor via the Lipid Bilayer

  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Quintana García, Aleix|||0000-0003-4472-5129
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
Molecular dynamic (MD) simulations have become a common tool to study the pathway of ligand entry to the orthosteric binding site of G protein-coupled receptors. Here, we have combined MD simulations and site-directed mutagenesis to study the binding process of the potent JWH-133 agonist to the cannabinoid CB receptor (CBR). In CBR, the N-terminus and extracellular loop 2 fold over the ligand binding pocket, blocking access to the binding cavity from the extracellular environment. We, thus, hypothesized that the binding pathway is a multistage process consisting of the hydrophobic ligand diffusing in the lipid bilayer to contact a lipid-facing vestibule, from which the ligand enters an allosteric site inside the transmembrane bundle through a tunnel formed between TMs 1 and 7 and finally moving from the allosteric to the orthosteric binding cavity. This pathway was experimentally validated by the Ala282 7.36 Phe mutation that blocks the entrance of the ligand, as JWH-133 was not able to decrease the forskolin-induced cAMP levels in cells expressing the mutant receptor. This proposed ligand entry pathway defines transient binding sites that are potential cavities for the design of synthetic modulators.